Cardiff Oncology, Inc. - Common Stock (CRDF) Institutional Ownership

13F Institutional Holders and Ownership History from Q2 2020 to Q4 2025

Type / Class
Equity / Common Stock
Symbol
CRDF on Nasdaq
Shares outstanding
66,577,393
Price per share
$1.62
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
27,248,502
Total reported value
$76,558,573
% of total 13F portfolios
0%
Share change
+2,135,081
Value change
+$6,434,989
Number of holders
108
Price from insider filings
$1.62
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Cardiff Oncology, Inc. - Common Stock (CRDF) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 5.8% +38% $10,678,250 +$2,780,523 3,841,097 +35% BlackRock, Inc. 31 Mar 2025
VANGUARD GROUP INC 5.6% $11,744,252 3,728,334 The Vanguard Group 30 Jun 2025
PFIZER INC 3.6% $6,704,178 2,411,575 Pfizer Inc. 13-5315170 31 Dec 2024

As of 31 Dec 2025, 108 institutional investors reported holding 27,248,502 shares of Cardiff Oncology, Inc. - Common Stock (CRDF). This represents 41% of the company’s total 66,577,393 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Cardiff Oncology, Inc. - Common Stock (CRDF) together control 38% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BlackRock, Inc. 6.1% 4,043,614 +1.5% 0% $11,362,555
VANGUARD GROUP INC 5.6% 3,722,085 +3.7% 0% $10,459,059
Laurion Capital Management LP 4% 2,646,738 +7.3% 0.51% $7,437,334
Pfizer Inc 3.6% 2,411,575 0% 2.9% $6,776,526
ACORN CAPITAL ADVISORS, LLC 2.9% 1,962,084 0% 1.9% $5,513,456
BLAIR WILLIAM & CO/IL 2.9% 1,948,847 -12% 0.01% $5,476,260
GEODE CAPITAL MANAGEMENT, LLC 2.3% 1,523,015 -1.3% 0% $4,280,748
FRANKLIN RESOURCES INC 1.8% 1,205,803 0% $3,388,306
STATE STREET CORP 1.8% 1,191,647 +4% 0% $3,348,528
TWO SIGMA INVESTMENTS, LP 1.1% 724,957 +255% 0% $2,037,129
FLPUTNAM INVESTMENT MANAGEMENT CO 0.89% 595,328 -0.32% 0.02% $1,672,872
NORTHERN TRUST CORP 0.69% 461,753 -11% 0% $1,297,526
GOLDMAN SACHS GROUP INC 0.58% 385,086 -15% 0% $1,082,092
TWO SIGMA ADVISERS, LP 0.54% 360,500 +1297% 0% $1,013,005
Candriam S.C.A. 0.52% 344,437 0% $967,909
Bank of New York Mellon Corp 0.49% 328,995 -5.3% 0% $924,476
MORGAN STANLEY 0.35% 235,833 -24% 0% $662,691
XTX Topco Ltd 0.33% 219,357 +40% 0.02% $616,393
GSA CAPITAL PARTNERS LLP 0.32% 210,880 0.05% $593,000
MILLENNIUM MANAGEMENT LLC 0.29% 194,420 +442% 0% $546,320
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.28% 188,655 -0.35% 0% $530,121
Avestar Capital, LLC 0.2% 136,145 -3.1% 0.03% $382,567
JANE STREET GROUP, LLC 0.2% 132,850 -18% 0% $373,308
CITADEL ADVISORS LLC 0.18% 118,188 +428% 0% $332,108
AlphaCore Capital LLC 0.17% 114,426 +4.1% 0.01% $321,537

Institutional Holders of Cardiff Oncology, Inc. - Common Stock (CRDF) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 27,248,502 $76,558,573 +$6,434,989 $2.81 108
2025 Q3 25,201,266 $51,916,152 -$9,684,486 $2.06 111
2025 Q2 28,660,334 $90,269,224 -$11,262,615 $3.15 114
2025 Q1 32,345,011 $101,559,895 +$10,196,300 $3.14 116
2024 Q4 28,092,578 $121,918,732 +$50,159,924 $4.34 117
2024 Q3 12,761,449 $34,074,638 -$895,795 $2.67 82
2024 Q2 13,089,737 $29,054,064 +$5,567,075 $2.22 90
2024 Q1 8,576,486 $45,797,587 +$17,940,647 $5.34 74
2023 Q4 5,309,425 $7,858,363 -$215,046 $1.48 55
2023 Q3 5,456,265 $7,583,910 -$756,925 $1.39 55
2023 Q2 5,991,988 $8,808,700 -$1,673,969 $1.47 50
2023 Q1 7,049,719 $11,633,255 -$748,502 $1.65 52
2022 Q4 7,699,341 $10,776,288 -$189,952 $1.40 55
2022 Q3 7,924,242 $12,205,032 -$1,956,121 $1.54 47
2022 Q2 8,925,020 $19,636,792 -$17,827,128 $2.20 54
2022 Q1 16,524,301 $40,953,207 -$30,166,620 $2.48 81
2021 Q4 22,015,576 $132,083,136 +$5,192,808 $6.01 81
2021 Q3 21,121,086 $140,722,888 -$35,953,961 $6.66 82
2021 Q2 26,525,986 $176,397,333 +$10,825,969 $6.65 81
2021 Q1 24,079,194 $222,960,463 -$69,848,932 $9.26 70
2020 Q4 26,636,620 $479,141,900 +$144,188,615 $17.99 79
2020 Q3 18,710,542 $265,500,071 +$207,902,213 $14.19 63
2020 Q2 4,923,525 $24,668,025 +$24,668,026 $5.01 23